LEGAL & GENERAL UCLEGAL & GENERAL UCLEGAL & GENERAL UC

LEGAL & GENERAL UC

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪17.52 M‬CHF
Fund flows (1Y)
Dividend yield (indicated)
Discount/Premium to NAV
1.09%
Shares outstanding
‪1.65 M‬
Expense ratio
0.49%

About LEGAL & GENERAL UC


Brand
L&G
Inception date
Jan 23, 2018
Structure
Irish VCIC
Index tracked
Solactive Pharma Breakthrough Value Index
Replication method
Physical
Management style
Passive
Dividend treatment
Capitalizes
Primary advisor
LGIM Managers (Europe) Ltd.
ISIN
IE00BF0H7608
The L&G Pharma Breakthrough UCITS ETF (the Fund) is an exchange traded fund (ETF) that aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the Index) subject to the deduction of the ongoing charges and other costs associated with operating the Fund.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Pharmaceuticals
Strategy
Multi-factor
Geography
Global
Weighting scheme
Equal
Selection criteria
Multi-factor

Returns


1 month3 monthsYear to date1 year3 years5 years
Price performance
NAV total return

What's in the fund


As of May 30, 2025
Exposure type
StocksBonds, Cash & Other
Health Technology
Stocks99.91%
Health Technology94.87%
Process Industries5.04%
Bonds, Cash & Other0.09%
Cash0.09%
Stock breakdown by region
55%24%19%
North America55.50%
Europe24.79%
Asia19.71%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings

Dividends


Dividend payout history

Assets under management (AUM)



Fund Flows



Frequently Asked Questions


ETLI invests in stocks. The fund's major sectors are Health Technology, with 94.87% stocks, and Process Industries, with 5.04% of the basket. The assets are mostly located in the North America region.
ETLI top holdings are BioCryst Pharmaceuticals, Inc. and Pharming Group NV, occupying 3.88% and 3.78% of the portfolio correspondingly.
No, ETLI doesn't pay dividends to its holders.
ETLI shares are issued by Legal & General Group Plc under the brand L&G. The ETF was launched on Jan 23, 2018, and its management style is Passive.
ETLI expense ratio is 0.49% meaning you'd have to pay 0.49% of your investment to help manage the fund.
ETLI follows the Solactive Pharma Breakthrough Value Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
ETLI invests in stocks.
ETLI price has fallen by −0.05% over the last month, and its yearly performance shows a 1.65% increase. See more dynamics on ETLI price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 1.25% over the last month, showed a −12.33% decrease in three-month performance and has decreased by −1.62% in a year.
ETLI trades at a premium (1.09%) meaning the ETF is trading at a higher price than the calculated NAV.